Company updateMoneycontrol
Motilal Oswal raises Symbiotec target to Rs 1800
Positive+5
GreyOak summary
Motilal Oswal raised its earnings estimates for Symbiotec Pharmalab, citing 16% YoY revenue growth and strong API segment profitability. The broker values the company at 45x forward earnings, setting a target price of Rs 1,800 and maintaining a BUY rating.
What it affects
- Symbiotec PharmalabSYMBIOTECPositive +5
Revenue grew 16% YoY; target raisedRolling sentiment Positive +29
Source
Read the original at MoneycontrolMore Symbiotec Pharmalab news
- Pharma stocks rally: Aurobindo, Divi's, Glenmark, Symbiotec hit new highsBusiness Standard · Stock view ·
- Symbiotec Pharma shares hit new high on Q2 resultsBusiness Standard · Results ·